Y-mabs Therapeutics

DANYELZA

  1. Home
  2.  / 
  3. J Code
  4.  / DANYELZA – J9348

Manufacturer:

Y-mabs Therapeutics

Name:

DANYELZA

HCPCS Code Descriptor:

Injection, naxitamab-gqgk, 1 mg

Category:

J Code

HCPCS:

J9348

NDC(s):

73042-0201-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

DANYELZA is an Oncology drug manufactured by Y-mabs Therapeutics and administered via the Intravenous route of administration. The J Code: J9348 is aligned to the drug DANYELZA.

Access Pricing and More By Registering

HCPCS Added Date:

7/1/21

HCPCS Effective Date:

7/1/21

HCPCS Short Description:

Inj. naxitamab-gqgk, 1 mg

Billing and Coding Guide:

https://danyelzahcp.com/wp-content/themes/DANYELZA_HCP_120/download-pdf/DANYELZA%20Billing_and_Coding_Guide_June2021.pdf

Patient Assistance:

https://ymabsconnect.com/